{"Clinical Trial ID": "NCT03273426", "Intervention": ["INTERVENTION 1:", "Basic needle biopsy", "A biopsy based on ultrasound needles (14G, 5 carrots recommended) for a complete clinical response (CCR) or near-CCR predicted by MRI.", "INTERVENTION 2:", "- Vacuum biopsy", "A vacuum biopsy (10G, 5 recommended cores) for a complete clinical response (CCR) or near-CCR predicted by MRI."], "Eligibility": ["Incorporation criteria:", "Patients", "\u2022 with unilateral primary cancer confirmed pathologically before neoadjuvant chemotherapy (NAC)", "\u25a1 who received the NAC", "With detectable injury / ultrasound clip marker", "With cT1-T3 tumours", "\u2022 Complete or near-complete clinical and imaging response to MRI", "With informed consent", "- Exclusion criteria:", "Multifocal cancer", "- Residual microcalcification", "Contralateral breast cancer"], "Results": ["Performance measures:", "Negative predictive value", "Percentage of participants with a complete pathological response (CPR) confirmed by surgical excision in patients whose biopsy predicts that they have SPC", "Time limit: 2 weeks", "Results 1:", "Title of the arm/group: Basic needle biopsy", "Description of the arm and group: Ultrasonic-guided heart-based needle biopsy (14G, 5 carrots recommended) for a complete clinical response (CCR) or near-CCR predicted by MRI.", "Total number of participants analysed: 17", "Type of measurement: Number", "Unit of measure: % of participants 88.2 (71.94 to 95.64)", "Results 2:", "Title of the arm/group: Vacuum biopsy", "Description of the arm/group: Aspirated biopsy (10G, 5 recommended cores) for a complete clinical response (CCR) or near-CCR predicted by MRI.", "Total number of participants analysed: 14", "Type of measurement: Number", "Unit of measure: percentage of participants 85.7 (64.37 to 95.22)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/20 (0.00 %)", "Adverse Events 2:", "Grand total"]}